Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Stocks are drifting in mixed trading on Wall Street Thursday after President Donald Trump's latest tariffs took effect on ...

The drugmaker posted revenue of $15.56 billion in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $14.75 billion. Lilly expects full-year earnings in the range of ...

Tariffs would disrupt international supply chains, forcing companies to decide whether to pass on increased costs to patients and exacerbate existing drug shortages.

Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...